HarborHawk

🎯HK stocks | Technical analysis, key levels & order flow. Watch the levels. Follow the flow.
⚠️ I never DM first or ask for money. Beware impersonators.

[HarborHawk @HarborHawkHK_2]

https://t.co/lBSDZ037aj jumped 14.3% as property-policy hopes lit up the tape. Momentum is real, but the easy chase is gone. Above HK$0.65, buyers confirm control; below HK$0.60, late money gets trapped. I’m mapping the next setup in the community. Trade levels—not hope.

[HarborHawk @HarborHawkHK_2]

https://t.co/t9HkmY4UtT crashed 13.3% on 2.8x volume after its Probio spin-off plan. This was distribution, not a routine dip. Above HK$33, buyers regain the tape; below HK$31.20, sellers press. I’m mapping the next setup in the community. Don’t catch falling knives.

[HarborHawk @HarborHawkHK_2]

https://t.co/PuPsoir6cx sank 9.2% to HK$38.14 while the HSI rose 1.7%. The IPO story is losing price discovery. Above HK$42, buyers can reset the tape; below HK$37.80, fresh lows open. I’m mapping the next setup in the community now. Trade the plan—not the pitch.

[HarborHawk @HarborHawkHK_2]

https://t.co/NE9eIGHsNT closed strong, but the chart still owes us one thing: HK$112.70. Above it, I’ll target HK$115–118. Below HK$107.50, the setup is dead. No chasing. Live levels and trade plans are in the community. Get the plan before the move—not after it. #HKstocks

[HarborHawk @HarborHawkHK_2]

$9926.HK jumped 11%—Keytruda may finally have a challenger. Akeso’s ivonescimab beat Merck’s drug on overall survival in Phase 3. My take: real clinical momentum, not biotech noise—but https://t.co/bwp0JA1rGR near HK$101 already prices in plenty Breakout or overreaction? #Biotech

[HarborHawk @HarborHawkHK_2]

$TSLA finally cleared the $366 ceiling—and the move had force.

Close: ~$376 | High: $384
Bull trigger: hold $370, then break $384
Targets: $400, then $410
Risk: lose $359

The breakout is live. Friday needs follow-through, not another headline spike. #TSLA #USStocks

[HarborHawk @HarborHawkHK_2]

$0013 surged 14.3%—but is the market still underpricing the deal?
HUTCHMED gets US$110M upfront from GSK, with up to US$1.185B in milestones
My take: real cash makes this more than biotech hype, but https://t.co/TLSCcr7t0k must reclaim HK$22.30
Rerating or one-day pop?
#Biotech

[HarborHawk @HarborHawkHK_2]

GSK put US$110m behind https://t.co/TLSCcr7t0k. Shares jumped 14.3% while the HSI fell 0.6%
My take: validation, not victory. The upfront is real cash. The US$1.2bn milestone headline is option value—not revenue—until Phase I delivers
Peers: https://t.co/djtqVqHyW5

[HarborHawk @HarborHawkHK_2]

https://t.co/TLSCcr7t0k This move has real money behind it.
HUTCHMED licensed an experimental cancer drug to GSK for a US$110M upfront payment.
My take: stronger than a routine biotech spike, but chasing here is risky. HK$22 is the real test.
Deal rerating or one-day pop?

[HarborHawk @HarborHawkHK_2]

IPO support is gone $0625 (https://t.co/xUXrkLmqaG) SHEIN is down 9.0% to HK$41.86—a fresh post-listing low and 13.8% below its HK$48.56 offer price. Below HK$43.70, sellers stay in control. Only a reclaim of HK$46.00 would repair the chart. No knife-catching yet #HKstocks #SHEIN

[HarborHawk @HarborHawkHK_2]

🚨 HK TAPE ALERT | $2259

Zijin Gold Intl surged 8.1% to HK$161.70 by midday, far ahead of the Hang Seng’s ~0.7% gain.
Gold’s rebound and softer USD/yields are amplifying the move. Watch HK$162.70 for a breakout; HK$153.20 is the session floor.
#HKStocks

[HarborHawk @HarborHawkHK_2]

$9988 Alibaba is still below its HK$112.70 placement price after fading to HK$108.80. Bias stays defensive below HK$110.70–112.70.
Reclaim: HK$116, then HK$120.
Lose HK$108.30: HK$105 comes into view.
Wait for confirmation.
#HKstocks #TechnicalAnalysis

[HarborHawk @HarborHawkHK_2]

The U.S. jobs machine just downshifted.
ADP private payrolls rose only 38K in August versus 48K expected, while manufacturing lost 17K jobs. Factory orders rebounded 0.9%, but core capital-goods orders were flat.
Softer labor. Hotter energy. A harder Fed call. #Fed

[HarborHawk @HarborHawkHK_2]

Copper owns the narrative. Zinc owns the squeeze.
LME zinc hit a 4-year high at $3,990/t. Registered stocks are only 100,525t, nearly one-third already cancelled for load-out, while H1 mine supply fell 2.6%.
This is scarcity happening now—not a 2030 forecast. #Zinc

[HarborHawk @HarborHawkHK_2]

India just built a $136.38B FX shield—far above the $80–90B expected.
Record reserves give the RBI more power to defend the rupee. But the same scheme lifted forward liabilities to $136.7B and adds domestic liquidity.
Stronger buffer now. Bigger bill later. #INR

[HarborHawk @HarborHawkHK_2]

Canada didn’t hike. Markets heard a hike anyway.
The BoC held at 2.25%, but 3.0% inflation and 3.3% Q2 growth pushed guidance in a hawkish direction. If energy stays elevated, tightening could restart.
The hold was not the message. The guidance was. #BoC

[HarborHawk @HarborHawkHK_2]

Washington wants the Iran war quiet. The battlefield disagrees.
Trump aides reportedly want it contained until November; 31% approve, while 63% disapprove.
But U.S.–Iran strikes have resumed. The political calendar is asking for calm the war may not give.

[HarborHawk @HarborHawkHK_2]

https://t.co/X0rCvcEQwc Slid 7.1% to HKD 20.88 on 26.4M shares, closing near the HKD 20.86 low as Chinese brokers sold off. With https://t.co/SfLmn3zmQs and https://t.co/ChtX8kNpLl also lower, this looks sector-wide. HKD 20.86 must hold; HKD 22.48 is the first meaningful reclaim.

[HarborHawk @HarborHawkHK_2]

https://t.co/anHIlzWVb7 SHEIN fell 3.1% to HKD 46.98 on day two, staying below its HKD 48.56 IPO price after a stabilisation-assisted debut.The market is still repricing tariff, margin and regulatory risk. Reclaiming HKD 48.56 would be the first sign that supply has been absorbed

[HarborHawk @HarborHawkHK_2]

https://t.co/8WY8ZV2HxP SUNeVision surged 15.1% to HKD 5.63 on 37.1M shares after FY profit rose 17% and revenue 6%. The move reflects real data-centre earnings, not just an AI headline. HKD 5.22 is first support; a break above HKD 5.74 would confirm follow-through.